Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a common disease with high morbidity and lacks effective treatment. We investigated the protective effects of the long-term application of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin on diabetes-associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Bin, Yu, Peiran, Yu, Hao, Qian, Buyun, Li, Yuan, Sun, Kangyun, Shi, Bimin, Zhang, Nannan, Xu, Guidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308685/
https://www.ncbi.nlm.nih.gov/pubmed/37386620
http://dx.doi.org/10.1186/s13098-023-01116-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308685/
https://www.ncbi.nlm.nih.gov/pubmed/37386620
http://dx.doi.org/10.1186/s13098-023-01116-8

Ejemplares similares